Despite a modest decrease in Byetta (exenatide) sales, Amylin Pharmaceuticals Inc. said it ended that quarter with strong revenues overall and soon will get a $125 million boost from a deal to supply partner Eli Lilly and Co. with a once-weekly version of the drug, upon approval. (BioWorld Today)